Logo image of KYMR

KYMERA THERAPEUTICS INC (KYMR) Stock Fundamental Analysis

NASDAQ:KYMR - Nasdaq - US5015751044 - Common Stock - Currency: USD

29.92  +1.12 (+3.89%)

Fundamental Rating

3

Overall KYMR gets a fundamental rating of 3 out of 10. We evaluated KYMR against 560 industry peers in the Biotechnology industry. The financial health of KYMR is average, but there are quite some concerns on its profitability. While showing a medium growth rate, KYMR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KYMR has reported negative net income.
In the past year KYMR has reported a negative cash flow from operations.
KYMR had negative earnings in each of the past 5 years.
KYMR had negative operating cash flow in 4 of the past 5 years.
KYMR Yearly Net Income VS EBIT VS OCF VS FCFKYMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -26.23%, KYMR is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
The Return On Equity of KYMR (-30.64%) is better than 77.14% of its industry peers.
Industry RankSector Rank
ROA -26.23%
ROE -30.64%
ROIC N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
KYMR Yearly ROA, ROE, ROICKYMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KYMR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYMR Yearly Profit, Operating, Gross MarginsKYMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
KYMR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KYMR has been increased compared to 5 years ago.
Compared to 1 year ago, KYMR has an improved debt to assets ratio.
KYMR Yearly Shares OutstandingKYMR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KYMR Yearly Total Debt VS Total AssetsKYMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 6.91 indicates that KYMR is not in any danger for bankruptcy at the moment.
KYMR has a better Altman-Z score (6.91) than 83.39% of its industry peers.
KYMR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of KYMR (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.91
ROIC/WACCN/A
WACC9.48%
KYMR Yearly LT Debt VS Equity VS FCFKYMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 8.49 indicates that KYMR has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.49, KYMR is doing good in the industry, outperforming 74.11% of the companies in the same industry.
A Quick Ratio of 8.49 indicates that KYMR has no problem at all paying its short term obligations.
KYMR has a better Quick ratio (8.49) than 74.11% of its industry peers.
Industry RankSector Rank
Current Ratio 8.49
Quick Ratio 8.49
KYMR Yearly Current Assets VS Current LiabilitesKYMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for KYMR have decreased strongly by -27.05% in the last year.
Looking at the last year, KYMR shows a very negative growth in Revenue. The Revenue has decreased by -25.85% in the last year.
The Revenue has been growing by 74.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.26%
Revenue 1Y (TTM)-25.85%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%114.83%

3.2 Future

The Earnings Per Share is expected to grow by 1.27% on average over the next years.
Based on estimates for the next years, KYMR will show a very strong growth in Revenue. The Revenue will grow by 62.42% on average per year.
EPS Next Y-27.43%
EPS Next 2Y-19.55%
EPS Next 3Y-11.82%
EPS Next 5Y1.27%
Revenue Next Year19.88%
Revenue Next 2Y14.25%
Revenue Next 3Y17.79%
Revenue Next 5Y62.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
KYMR Yearly Revenue VS EstimatesKYMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
KYMR Yearly EPS VS EstimatesKYMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KYMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KYMR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYMR Price Earnings VS Forward Price EarningsKYMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYMR Per share dataKYMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

KYMR's earnings are expected to decrease with -11.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.55%
EPS Next 3Y-11.82%

More info and screens

0

5. Dividend

5.1 Amount

KYMR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (5/29/2025, 2:40:12 PM)

29.92

+1.12 (+3.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners111.32%
Inst Owner Change2.05%
Ins Owners1.3%
Ins Owner Change2.42%
Market Cap1.95B
Analysts84.8
Price Target59.5 (98.86%)
Short Float %11.37%
Short Ratio9.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.43%
Min EPS beat(2)-11.39%
Max EPS beat(2)12.26%
EPS beat(4)3
Avg EPS beat(4)5.45%
Min EPS beat(4)-11.39%
Max EPS beat(4)16.79%
EPS beat(8)5
Avg EPS beat(8)4.61%
EPS beat(12)6
Avg EPS beat(12)2.01%
EPS beat(16)6
Avg EPS beat(16)-6.94%
Revenue beat(2)1
Avg Revenue beat(2)37.35%
Min Revenue beat(2)-38.67%
Max Revenue beat(2)113.36%
Revenue beat(4)2
Avg Revenue beat(4)27.6%
Min Revenue beat(4)-64.6%
Max Revenue beat(4)113.36%
Revenue beat(8)4
Avg Revenue beat(8)5.02%
Revenue beat(12)4
Avg Revenue beat(12)-6.78%
Revenue beat(16)5
Avg Revenue beat(16)-9.67%
PT rev (1m)0.67%
PT rev (3m)-1.04%
EPS NQ rev (1m)2.3%
EPS NQ rev (3m)-9.34%
EPS NY rev (1m)2.06%
EPS NY rev (3m)-18.9%
Revenue NQ rev (1m)20.08%
Revenue NQ rev (3m)7.47%
Revenue NY rev (1m)14.24%
Revenue NY rev (3m)-9.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.09
P/FCF N/A
P/OCF N/A
P/B 2.48
P/tB 2.48
EV/EBITDA N/A
EPS(TTM)-3.1
EYN/A
EPS(NY)-4.14
Fwd EYN/A
FCF(TTM)-3.68
FCFYN/A
OCF(TTM)-3.59
OCFYN/A
SpS0.9
BVpS12.07
TBVpS12.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.23%
ROE -30.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 74.16%
Cap/Sales 10.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.49
Quick Ratio 8.49
Altman-Z 6.91
F-Score1
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)412.2%
Cap/Depr(5y)364.06%
Cap/Sales(3y)25.74%
Cap/Sales(5y)21.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.26%
EPS Next Y-27.43%
EPS Next 2Y-19.55%
EPS Next 3Y-11.82%
EPS Next 5Y1.27%
Revenue 1Y (TTM)-25.85%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%114.83%
Revenue Next Year19.88%
Revenue Next 2Y14.25%
Revenue Next 3Y17.79%
Revenue Next 5Y62.42%
EBIT growth 1Y-60.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.49%
EBIT Next 3Y-13.9%
EBIT Next 5YN/A
FCF growth 1Y-47.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.27%
OCF growth 3YN/A
OCF growth 5YN/A